Providers

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Doctors performing surgery with AI graphics | Image credit: Framestock – stock.adobe.com
How the Human Touch Boosts AI Surgical Training

August 6th 2025

In follow-up PET/CTs, the investigators said those with complete metabolic remissions tended to have superior PFS. | Image credit: Saiful52 - stock.adobe.com
PET/CT Helps Predict Relapse in Patients With Myeloma Undergoing CAR T-Cell Therapy

August 5th 2025

Beyond well-characterized cellular and molecular pathways, the authors explore the emerging significance of non-coding RNAs. | Image credit: PRASANNAPIX - stock.adobe.com
Insights Into Pulmonary Fibrosis Pathogenesis, Treatments, and the Potential Role of Traditional Chinese Medicine

August 5th 2025

ROS1-positive NSCLC is aggressive and rare, with approximately 3000 new diagnoses of advanced disease in the US each year. | Image credit: appledesign - stock.adobe.com
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

July 31st 2025

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo